CMPS heads into the week of July 8 with a wave of bullish analyst action reshaping the Street narrative — even as the stock pulls back 8% on the week and earnings loom on July 30.
The analyst story is the standout this week, and it cuts sharply in one direction. Evercore ISI upgraded CMPS to Outperform from In-Line on July 8, lifting its target from $8 to $21 — more than a 160% jump in the price objective. Stifel raised its target the same morning from $14 to $21 while staying at Buy. BTIG also raised from $14 to $25. Those three moves all landed within 24 hours. HC Wainwright reiterated its $70 target, though that figure sits far above the pack and likely reflects assumptions that are materially more optimistic than consensus. Stripping that outlier aside, the cluster of $20–$25 targets implies roughly 60–90% upside from the current $12.99 close. Morgan Stanley and Oppenheimer held their existing Overweight and Outperform ratings steady. Every active analyst is at Buy or equivalent — twelve buys, zero holds.
The bull case centers on COMP360, the company's psilocybin treatment for treatment-resistant depression, and an FDA pathway that the Street increasingly views as credible. Analysts point to a potential $1.4 billion peak sales opportunity if the VA indication in PTSD advances, and to cash runway extending into 2028 giving CMPS time to reach key regulatory milestones. The bear case is narrower but real: commercialization infrastructure for psychedelic therapies remains untested at scale, REMS requirements could complicate rollout, and the company carries deeply negative earnings — the EV/EBITDA sits at -7.75 and PE at -12.24, consistent with a clinical-stage name valued on probability-weighted pipelines rather than current cash flows. The price-to-book multiple of 6.1x has expanded roughly 6% over the past month, reflecting the stock's 7% gain since early June.
Positioning in the lending market is conspicuously relaxed, which makes the week's analyst noise stand out even more by contrast. Availability is running at 881% — meaning there are nearly nine shares available to borrow for every share already borrowed. Borrow costs ticked up 30% on the week but remain negligible at 0.49%. Short interest has risen about 4.7% over the past month to roughly 8.4 million shares, a gentle drift higher rather than an aggressive build. The days-to-cover figure from the latest FINRA settlement is 2.2 days — not a name where a squeeze dynamic is present. This is not a crowded short. The borrow market is wide open.
Options traders tell a similarly calm story. The put/call ratio is running at 0.14, well below its 20-day average of 0.17 — the lowest reading in nearly a year — suggesting options activity is dominated by calls rather than protective puts. That aligns with the analyst upgrade wave: the market is leaning toward upside positioning ahead of the July 30 earnings date. The ORTEX short score has nudged up to 53.6 from 51.1 a week ago, a modest drift higher that is not yet signalling meaningful short pressure. On the factor side, the days-to-cover rank of 81 stands out — that metric captures the ease of unwinding short positions, and a high rank here reinforces the picture of a name where short positioning is neither aggressive nor trapped.
The institutional register has some notable colour. Deep Track Capital holds 9% of shares and added nearly 4.8 million shares in Q1. RTW Investments holds 7.9% and added 1.9 million. Marshall Wace and Tang Capital each appear to have initiated positions in Q1 with fresh holdings above 4 million shares apiece. ARK Investment Management added over 1.1 million shares through June, the most recently updated figure in the register. The CEO and CFO both made small scheduled sales in March — low significance, small dollar amounts, not a signal. The overall ownership picture is one of specialist biotech and healthcare funds building rather than trimming.
The last two earnings prints are worth noting without reading too much into them. The May 13 release drove a 13.3% one-day gain and a 16% five-day move. The May 7 print generated a 1.5% one-day move and an 8.8% five-day gain. Both were positive reactions. The July 30 report will be the next test of whether the analyst community's upgraded confidence in COMP360's regulatory path is finding any corroboration in the underlying data — that is what the market will be focused on.
See the live data behind this article on ORTEX.
Open CMPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
